✦ LIBER ✦

Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response

✍ Scribed by S. Osorio; A. García Noblejas; A. Durán; J.L. Steegmann

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 73 KB
Volume: 82
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.20778

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

XPC genetic polymorphisms correlate with

XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia

✍ Vicent M. Guillem; Francisco Cervantes; Jesús Martínez; Alberto Alvarez-Larrán; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Clinical course of thrombocytopenia in p

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia

✍ Hendrik W. van Deventer; Melissa D. Hall; Robert Z. Orlowski; Beverly S. Mitchel 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

The relationship between telomere length

The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia

✍ Hiroshi Iwama; Kazuma Ohyashiki; Junko H. Ohyashiki; Shigefumi Hayashi; Ken Kawa 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## RESULTS. At the time of CML diagnosis, 19 patients had TRFs within the age-Medical College, Tokyo, Japan. matched normal range (mean { 2 1 standard deviation [SD]) and the remaining 2 Department of Cell Biology and Neuroscience, 25 patients had TRFs shorter than the age-matched normal range (õ

Response to therapy is independently ass

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase

✍ Hagop M. Kantarjian; Jianqin Shan; Terry Smith; Moshe Talpaz; Peter Kozuch; Mary 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

Sustained remissions and low rate of BCR

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up

✍ Georg Hess; Ralf G. Meyer; Brigitte Schuch; Katja Bechthold; Ilse El-Kholy; Chri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 1 views

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 1 views